泽璟制药-U (688266.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 31.19B

MomentumView details →

1D Return

−8.45%

YTD Return

—

RSI (14)

47.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 31.19B

RSI (14)

47.3

MomentumView details →

1D Return

−8.45%

YTD Return

—

ProfitabilityView details →

Gross Margin

94.50%

Net Margin

32.16%

EBITDA Margin

−7.76%

ROE (TTM)

29.07%

ROA (TTM)

13.50%

Asset Turnover

0.47x

GrowthView details →

Revenue YoY

+161.37%

EPS YoY

+490.40%

FCF YoY

+505.15%

Revenue CAGR 3Y

+38.92%

EPS CAGR 3Y

−19.23%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.03

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−0.50%

Capital & dividendView details →

Debt/Equity

0.55x

Current Ratio

2.36x

Quick Ratio

2.23x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.55B

Net Income (TTM)

497.93M

Op. CF (TTM)

814.89M

Next earningsOct 26, 2026 →

Latest newsMore news →

Zelgen Pharmaceuticals reported first-half 2026 revenue of 550 million yuan from four marketed innovative drugs, up 44.3% year-on-year.17d ago

Zelgen Biopharmaceuticals disclosed H1 revenue of 1.205 billion yuan, up 220.88% year-over-year, with net profit of 640 million yuan, turning from loss to profit.19d ago

Similar companies

Simcere Pharmaceutical Group Limited02096.HK Royalty Pharma plcRPRX Insmed IncorporatedINSM 万泰生物603392.SH Alnylam Pharmaceuticals, Inc.ALNY 君实生物-U688180.SH Find similar companies →

Latest newsMore news →

Zelgen Pharmaceuticals reported first-half 2026 revenue of 550 million yuan from four marketed innovative drugs, up 44.3% year-on-year.17d ago Zelgen Biopharmaceuticals disclosed H1 revenue of 1.205 billion yuan, up 220.88% year-over-year, with net profit of 640 million yuan, turning from loss to profit.19d ago Zelgen Biopharmaceuticals reached a BD collaboration with AbbVie on ZG006, recognizing 662 million yuan in technology licensing revenue, with both parties accelerating global development.19d ago